Key result
Sleeve gastrectomy significantly improved glucose homeostasis in patients with morbid obesity and impaired glucose regulation, reducing median A1C from 7.4% to 5.8% at 6 months postoperatively.
Why the study?
Detailed dynamic changes in glucose and insulin homeostasis in relation to incretin hormones GIP and GLP-1 following sleeve gastrectomy had not been examined in this number of participants.
Does sleeve gastrectomy improve glucose-insulin homeostasis and incretin hormone response in patients with impaired glucose tolerance and type 2 diabetes?
Observational (n=55)
No
Does sleeve gastrectomy improve glucose-insulin homeostasis and incretin hormone response in patients with impaired glucose tolerance and type 2 diabetes?
Sleeve gastrectomy significantly improves glucose-insulin homeostasis and increases GLP-1 response as early as 1 to 6 months postoperatively in patients with obesity and impaired glucose regulation.
BACKGROUND: Bariatric surgery is an effective treatment for morbid obesity and glycaemic dysfunction. OBJECTIVES: The aim of the work was to examine both the static and dynamic changes of glucose-insulin homeostasis and incretin hormone response following sleeve gastrectomy (SG) in a sample of 55 participants preoperatively and 1 month and 6 months postoperatively. The focus was on a sample of patients with impaired glucose tolerance and type 2 diabetes (T2D). SETTING: Morriston Hospital, UK. Serial measurements of glucose, insulin, C-peptide, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic hormone (GIP) were performed during oral glucose tolerance testing preoperatively and 1 and 6 months postoperatively. Areas under the curve (AUC) were examined at 30, 60, and 120 min. RESULTS: We observed significant improvements in measures of obesity, as well as static and dynamic measures of glucose, insulin, C-peptide and HOMA. Furthermore, significant increases in GLP-1 response as early as 6 months postoperatively were also seen. CONCLUSIONS: To our knowledge, no study has examined the detailed dynamic changes in glucose and insulin homeostasis in this number of participants undergoing SG in relation to incretin hormones GIP and GLP-1. This current study supports the role of SG for the treatment of obesity-related glucose dysregulation.
No takes yet. Share an insight, caveat, or question.
Prior et al. (2020) conducted an observational in Impaired glucose regulation and type 2 diabetes with morbid obesity (n=55). Sleeve gastrectomy vs. Preoperative baseline was evaluated on Glycated haemoglobin (A1C) (p=<0.001). Sleeve gastrectomy significantly improved glucose homeostasis in patients with morbid obesity and impaired glucose regulation, reducing median A1C from 7.4% to 5.8% at 6 months postoperatively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: